The 5th International Molecular Pathological Epidemiology (MPE) Meeting (virtual) on May 24 to 25, 2021 was great success.
The 6th International Molecular Pathological Epidemiology (MPE) Meeting (in 2023) is under planning.
The International Molecular Pathological Epidemiology (MPE) Meeting Series is open to the international research community with free registration. The meeting series was launched in Boston, Massachusetts, U.S.A. in 2013. Read about past meetings.
Please also see:
Molecular Pathological Epidemiology (wikipedia)
Program in MPE Molecular Pathological Epidemiology (Department of Pathology, Brigham and Women's Hospital) (co-host of the International MPE Meeting Series with Dana-Farber Cancer Institute)
INTRODUCTION to The International Molecular Pathological Epidemiology (MPE) Meeting Series
The purpose of the meeting series is to:
Develop methods to integrate pathology and epidemiology
- Link pathogenic insights to population impact
- Educate next-generation scientists
As an important premise of epidemiology, individuals with the same disease generally have similar causes and exhibit a similar disease evolution. In the past few decades, our knowledge of disease pathogenesis has improved considerably, and disease classification has also transformed, incorporating molecular mechanisms of disease. As a result, pathology and epidemiology have been integrated into the single unified field of MPE. This has opened up enormous opportunities.
Advancing integrative molecular and population-level health science and addressing the unique research challenges specific to the field of MPE requires bringing together experts in diverse fields, including pathology, epidemiology, biostatistics, computational biology, bioinformatics, genomics, immunology, and nutritional and environmental sciences.
Integrating seemingly divergent fields can lead to a greater understanding of pathogenic processes and the impact of environmental, dietary, lifestyle, and genetic factors and their interactions. The Meeting Series fosters discussion and exchanges to advance development of new methodologies that address the unique research questions and challenges in this emerging field.
This unique meeting provides an unprecedented opportunity for interdisciplinary collaboration and integration of multiple diverse fields.
The international MPE Meeting Series has been supported by following agencies, institutions, schools, and corporations:
US National Institutes of Health; including National Cancer Institute (NCI), National Human Genome Research Institute (NHGRI), National Institute of Environmental Health Sciences (NIEHS) (grant No. R13 CA203287) for the 3rd meeting. NIH/NCI grant R35 CA197735 (PI, Shuji Ogino) has been supporting time efforts.
Dana-Farber Cancer Institute
Dana-Farber Harvard Cancer Center
Brigham and Women's Hospital (Department of Pathology)
Harvard T.H. Chan School of Public Health (Department of Epidemiology)
Bristol-Myers Squibb Company; QIAGEN, Inc.; Haoshengyibai Jiyin keji youxiangongsi; XtalPi, inc.; Creative Biosciences; Genecast; Precision Scientific Co., Ltd.; N-of-One; Sema4; TissueMark (for the 4th meeting)
Perkin Elmer Inc; NeoGenomics Laboratories; NanoString Technologies, Inc; Thermo Fisher Scientific, Inc. (for the 3rd meeting)
Enzymatics (for the 2nd meeting)